Skip to content

Bruker BRKR Cash Paid For In Process Research And Development And Related Assets

Cash Paid For In Process Research And Development And Related Assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$96.25M-78.4%
Viatris logo
ViatrisVTRS
-$6M+60.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$10.63M
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$71.94M
Roivant Sciences logo
Roivant SciencesROIV
$0
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO.B

Other financials

Income statement

See full
Revenue$823.4M+2.7%
Gross profit$379.8M-2.9%
Operating income$10.2M-67.9%
Net income$14.4M-17.2%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$137.6M-26.7%
Total debt$1.7B-20.9%
Total equity$2.5B+34.6%
Total assets$6.1B+3.3%

Cash flow

See full
Operating cash flow$71.2M+9.5%
CapEx$24.2M-6.9%
Free cash flow$47.0M+20.5%

Valuation

See full
Market cap$8.71B-13.2%
Enterprise value$10.25B-14.9%
P/S2.5×-0.4×

Profitability

See full
Gross margin45.3%-3.7pp
Operating margin1.3%-5.0pp
Net margin-0.6%-10.0pp
FCF margin1.5%-3.6pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.7×-0.5×
Current ratio1.6×0.0×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept brkr:CashPaidForInProcessResearchAndDevelopmentAndRelatedAssets.

The official record: Bruker’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's cash paid for in process research and development and related assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bruker's cash paid for in process research and development and related assets?
Bruker (BRKR) reported cash paid for in process research and development and related assets of $7.35M in Q4 2025.
What does cash paid for in process research and development and related assets mean?
Cash spent to acquire ongoing research and development projects from other entities.
How do you interpret cash paid for in process research and development and related assets?
An increase suggests aggressive pursuit of external innovation, while a decrease may indicate a focus on internal R&D or reduced acquisition activity.
How does cash paid for in process research and development and related assets compare across companies?
Common in life sciences and biotech firms; peers often report this as part of their broader M&A or R&D strategy.